HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR

Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR explained in plain language.

Never miss a new study

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR trials appear

Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Gene test may spare Low-Risk breast cancer patients from chemo

Knowledge-focused Ongoing

This study follows over 1,100 women with early-stage, hormone-sensitive breast cancer to see if those with a low-risk result on the EndoPredict® gene test can safely avoid chemotherapy and use only hormone therapy. Researchers are tracking whether these patients remain cancer-fre…

Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR

Sponsor: North Eastern German Society of Gynaecological Oncology • Aim: Knowledge-focused

Last updated Apr 30, 2026 15:52 UTC

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR

Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE TUMOR trials appear

Gene test may spare Low-Risk breast cancer patients from chemo